Recommendation ID
IPG401/1
Question
Safety of selective internal radiation therapy (SIRT) is a potentially beneficial treatment for patients with on-resectable colorectal metastases in the liver, but that more research and data collection are required to demonstrate its efficacy.
Any explanatory notes
(if applicable)
For patients who have previously been treated with chemotherapy, comparative trials are needed to determine whether SIRT prolongs survival compared with best standard treatment, and to determine its effect on quality of life. There is also a need to identify which subgroups of patients are likely to derive clinical benefit from SIRT. Research studies should clearly describe the characteristics of treated patients, and the extent and histological details of their tumours. Outcomes should include survival and quality of life. Downstaging of metastases allowing resection or ablation should be clearly documented.

Source guidance details

Comes from guidance
Selective internal radiation therapy for non-resectable colorectal metastases in the liver
Number
IPG401
Date issued
July 2011

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No